Next Article in Journal
The Proliferation and Differentiation of Adipose-Derived Stem Cells in Neovascularization and Angiogenesis
Previous Article in Journal
Molecular Research on Platelet Activity in Health and Disease
Article

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

1
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy
2
Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
3
Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
4
Unit of Gynecological Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(11), 3805; https://doi.org/10.3390/ijms21113805
Received: 23 April 2020 / Revised: 19 May 2020 / Accepted: 22 May 2020 / Published: 27 May 2020
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). In the absence of direct comparison, we performed a network meta-analysis considering BRCA genes status. Methods: We searched PubMed, EMBASE, and MEDLINE for trials involving patients with PS rOC treated with BEV or PARPi. Different comparisons were performed for patients included in the PARPi trials, according to BRCA genes status as follows: all comers (AC) population, BRCA 1/2 mutated (BRCAm), and BRCA wild type patients (BRCAwt). Results: In the overall population, PARPi prolonged PFS with respect to BEV (hazard ratio (HR) = 0.70, 95% CI 0.54–0.91). In the BRCA mutated carriers, the PFS improvement in favor of PARPi appeared to be higher (HR = 0.46, 95% CI 0.36–0.59) while in BRCAwt patients the superiority of PARPi over BEV failed to reach a statistically significance level (HR = 0.87, 95% CI 0.63–1.20); however, according to the SUCRA analysis, PARPi had the highest probability of being ranked as the most effective therapy (90% and 60%, for PARPi and BEV, respectively). Conclusions: PARPi performed better as compared with BEV in terms of PFS for the treatment of PS rOC, especially in BRCAm patients who had not previously received PARPi. View Full-Text
Keywords: platinum-sensitive ovarian cancer; bevacizumab; PARP-inhibitors platinum-sensitive ovarian cancer; bevacizumab; PARP-inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Bartoletti, M.; Pelizzari, G.; Gerratana, L.; Bortot, L.; Lombardi, D.; Nicoloso, M.; Scalone, S.; Giorda, G.; Baldassarre, G.; Sorio, R.; Puglisi, F. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int. J. Mol. Sci. 2020, 21, 3805. https://doi.org/10.3390/ijms21113805

AMA Style

Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences. 2020; 21(11):3805. https://doi.org/10.3390/ijms21113805

Chicago/Turabian Style

Bartoletti, Michele, Giacomo Pelizzari, Lorenzo Gerratana, Lucia Bortot, Davide Lombardi, Milena Nicoloso, Simona Scalone, Giorgio Giorda, Gustavo Baldassarre, Roberto Sorio, and Fabio Puglisi. 2020. "Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis" International Journal of Molecular Sciences 21, no. 11: 3805. https://doi.org/10.3390/ijms21113805

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop